drugset / Trial / NCT02223598
A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety, tolerability, dose limiting toxicities, and maximum tolerated dose of CB-5083 in subjects with lymphoid hematological malignancies.
Timeline
- Start
- 2014-08-25
- Primary completion
- 2017-07-26
- Completion
- 2017-07-26
Outcome
Outcome not reported
Stopped: “MTD determined”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CB-5083 | Small molecule | — | Oral |
| Background | Dexamethasone | Small molecule | 40 mg | Oral |